JP2024540445A5 - - Google Patents
Info
- Publication number
- JP2024540445A5 JP2024540445A5 JP2024528510A JP2024528510A JP2024540445A5 JP 2024540445 A5 JP2024540445 A5 JP 2024540445A5 JP 2024528510 A JP2024528510 A JP 2024528510A JP 2024528510 A JP2024528510 A JP 2024528510A JP 2024540445 A5 JP2024540445 A5 JP 2024540445A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- compound according
- ethyl
- pyridazin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21208773 | 2021-11-17 | ||
| EP21208773.8 | 2021-11-17 | ||
| PCT/EP2022/081866 WO2023088856A1 (en) | 2021-11-17 | 2022-11-15 | Heterocyclic nlrp3 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024540445A JP2024540445A (ja) | 2024-10-31 |
| JP2024540445A5 true JP2024540445A5 (OSRAM) | 2025-10-24 |
Family
ID=78676487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024528510A Pending JP2024540445A (ja) | 2021-11-17 | 2022-11-15 | 複素環式ｎｌｒｐ３阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240409553A1 (OSRAM) |
| EP (1) | EP4433480A1 (OSRAM) |
| JP (1) | JP2024540445A (OSRAM) |
| CN (1) | CN118234730A (OSRAM) |
| AR (1) | AR127705A1 (OSRAM) |
| TW (1) | TW202334153A (OSRAM) |
| WO (1) | WO2023088856A1 (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| US20240391881A1 (en) * | 2021-09-30 | 2024-11-28 | Origiant Pharmaceutical Co., Ltd. | Pharmaceutical use and preparation method for substituted heteroaryl phthalazine derivative |
| US20260015357A1 (en) * | 2022-07-01 | 2026-01-15 | Neumora Therapeutics, Inc. | Modulators of nlrp3 inflammasome and related products and methods |
| CN116789674B (zh) * | 2022-08-24 | 2024-05-24 | 杭州高光制药有限公司 | Nlrp3炎性小体抑制剂 |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| CN121045190A (zh) * | 2022-11-04 | 2025-12-02 | 药捷安康(南京)科技股份有限公司 | Nlrp3炎症小体抑制剂及其应用 |
| EP4644392A1 (en) * | 2022-12-27 | 2025-11-05 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pyridazine fused aryl ring compound and use thereof |
| WO2025026252A1 (en) * | 2023-08-02 | 2025-02-06 | Hangzhou Highlightll Pharmaceutical Co., Ltd | Nlrp3 inflammasome inhibitors |
| WO2025133307A1 (en) * | 2023-12-22 | 2025-06-26 | Ac Immune Sa | Heterocyclic modulators of the nlrp3 inflammasome pathway |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
| WO2025153624A1 (en) * | 2024-01-17 | 2025-07-24 | Ac Immune Sa | Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway |
| WO2025153625A1 (en) * | 2024-01-17 | 2025-07-24 | Ac Immune Sa | Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway |
| WO2026057747A1 (en) | 2024-09-11 | 2026-03-19 | Ac Immune Sa | Therapeutic use of nlrp3 inflammasome pathway inhibitor compounds |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2868780B1 (fr) * | 2004-04-13 | 2008-10-17 | Sanofi Synthelabo | Derives de la 1-amino-phthalazine, leur preparation et leur application en therapeutique |
| WO2018221433A1 (ja) * | 2017-05-29 | 2018-12-06 | 第一三共株式会社 | ヘテロアリールアミン誘導体 |
| UY38687A (es) * | 2019-05-17 | 2023-05-15 | Novartis Ag | Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso |
| JP7843705B2 (ja) | 2020-01-22 | 2026-04-10 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｎｌｒｐ３モジュレーターとしてのスルホンイミドアミド化合物 |
| US20240327413A1 (en) | 2021-06-29 | 2024-10-03 | Zomagen Biosciences Ltd | Nlrp3 modulators |
| TW202319055A (zh) | 2021-07-21 | 2023-05-16 | 日商安斯泰來製藥股份有限公司 | 縮環噠嗪（ｐｙｒｉｄａｚｉｎｅ）化合物 |
| PE20241727A1 (es) | 2021-08-25 | 2024-08-19 | Ptc Therapeutics Inc | Inhibidores de nlrp3 |
| US20240391881A1 (en) | 2021-09-30 | 2024-11-28 | Origiant Pharmaceutical Co., Ltd. | Pharmaceutical use and preparation method for substituted heteroaryl phthalazine derivative |
| WO2023066377A1 (zh) | 2021-10-22 | 2023-04-27 | 索智生物科技（浙江）有限公司 | 一种含氮化合物、其制备方法及应用 |
-
2022
- 2022-11-15 EP EP22818255.6A patent/EP4433480A1/en active Pending
- 2022-11-15 JP JP2024528510A patent/JP2024540445A/ja active Pending
- 2022-11-15 CN CN202280075550.2A patent/CN118234730A/zh active Pending
- 2022-11-15 WO PCT/EP2022/081866 patent/WO2023088856A1/en not_active Ceased
- 2022-11-16 TW TW111143745A patent/TW202334153A/zh unknown
- 2022-11-17 AR ARP220103167A patent/AR127705A1/es unknown
-
2024
- 2024-05-15 US US18/665,390 patent/US20240409553A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230120185A1 (en) | Heterocyclic amides as kinase inhibitors | |
| US20240139194A1 (en) | Preparation and methods of use for ortho-aryl 5-membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors | |
| US10030027B2 (en) | Soluble guanylate cyclase stimulators | |
| US20200339571A1 (en) | Heterocyclic compounds and uses thereof | |
| JP7675519B2 (ja) | キナーゼを調節するための化合物の固体形態 | |
| JP5128019B1 (ja) | オキサジン誘導体および神経障害の処置におけるその使用 | |
| JP5767214B2 (ja) | オキサジン誘導体および神経障害の処置のためのｂａｃｅ阻害剤としてのその使用 | |
| US20190345138A1 (en) | Heterocyclic amides as kinase inhibitors | |
| JP2010513283A (ja) | 新規なオキサジアゾール化合物 | |
| JP2024522494A5 (OSRAM) | ||
| US20240139158A1 (en) | Methods of treating pulmonary diseases and disorders | |
| JP6527851B2 (ja) | ロイコトリエンａ４加水分解酵素を阻害する方法 | |
| JP2014505688A (ja) | オキサジン誘導体および神経障害の処置におけるその使用 | |
| TW201619159A (zh) | 吡咯并［２，３－ｄ］嘧啶衍生物 | |
| JP2019504901A5 (OSRAM) | ||
| JP2013512951A (ja) | 新規オキサジアゾール化合物 | |
| JP2017523223A5 (OSRAM) | ||
| JP2022521081A (ja) | Ｈｂｖ感染若しくはｈｂｖ誘導性疾患の治療において有用なアミド誘導体 | |
| US11897876B2 (en) | Isoxazolidines as RIPK1 inhibitors and use thereof | |
| TW201815791A (zh) | 雜環化合物及其預防或治療細菌感染之用途 | |
| WO2019224774A1 (en) | Heterocyclic amides as rip1 kinase inhibitors | |
| US8835470B2 (en) | Mandelamide heterocyclic compounds | |
| CN102088976B (zh) | 包含毒蕈碱性受体拮抗剂和β2-肾上腺素受体激动剂的药物产品 | |
| US9650377B2 (en) | Diazepinone derivatives | |
| US20220273666A1 (en) | Nanoparticle formulation of bcl-2 inhibitor |